Skip to main content
. 2019 Apr 23;11:3445–3453. doi: 10.2147/CMAR.S191199

Figure 3.

Figure 3

OS and PFS times according to changes (Δ) in inflammatory markers after pazopanib treatment: ΔNLR (A, B), ΔDNLR (C, D), ΔLMR (E, F), and ΔPLR (G, H).

Abbreviations: OS, overall survival; PFS, progression-free survival; NLR, neutrophil-to-lymhocyte ratio; DNLR, derived neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; PLR, platelet-to-lymphocyte ratio.